{"nctId":"NCT00441545","briefTitle":"Head to Head Study Against Sevelamer Hydrochloride","startDateStruct":{"date":"2007-01-05","type":"ACTUAL"},"conditions":["Chronic Kidney Disease, Stage 5"],"count":182,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Fosrenol (Lanthanum Carbonate)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sevelamer hydrochloride"]}],"interventions":[{"name":"Fosrenol (Lanthanum Carbonate)","otherNames":["FOSRENOL"]},{"name":"Sevelamer hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with end stage renal disease who are receiving dialysis\n\nExclusion Criteria:\n\n* Subjects with significant gastrointestinal disorders\n* Subjects who are pregnant or nursing\n* Subjects currently taking lanthanum carbonate, sevelamer hydrochloride, cinacalcet hydrochloride\n* Subjects who are HIV positive\n* Subjects with clinical significant liver disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Serum Phosphorus Levels at 4 Weeks","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"0.129"},{"groupId":"OG001","value":"-1.44","spread":"0.132"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Calcium Levels at 4 Weeks","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.045"},{"groupId":"OG001","value":"-0.06","spread":"0.046"}]}]}]},{"type":"SECONDARY","title":"Levels of Intact Parathyroid Hormone (iPTH) at Baseline and 4 Weeks","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225.46","spread":"11.094"},{"groupId":"OG001","value":"225.46","spread":"11.094"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296.48","spread":"17.412"},{"groupId":"OG001","value":"291.18","spread":"16.181"}]}]}]},{"type":"SECONDARY","title":"Patients Achieving Kidney Disease Outcomes Quality Initiative (KDOQI) Target for Serum Phosphorous at 4 Weeks","description":"Kidney Disease Outcomes Quality Initiative (KDOQI) target for serum phosphorous is 3.5 - 5.5 mg/dL (1.13 - 1.77 mmol/L)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.7","spread":null},{"groupId":"OG001","value":"34.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":170},"commonTop":["Nausea","Diarrhea","Vomiting"]}}}